Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

I. Majer · SciRah

Researcher profile · Semantic Scholar

I. Majer

Share profile

I. Majer — researcher profile on SciRah

h-index: 13
Works: 63
Citations: 630

Most-cited papers

Mortality risk associated with disability: a population-based record linkage study.
I. Majer, W. Nusselder, J. Mackenbach, B. Klijs +1 more
2011American Journal of Public Health112 citations Open access
Semantic Scholar
Epidemiology of osteoporosis related fractures in Hungary from the nationwide health insurance database, 1999–2003
M. Péntek, C. Horváth, I. Boncz, Z. Falusi +5 more
2008Osteoporosis International77 citations
Semantic Scholar
Cost-Effectiveness of a Chemoprophylactic Intervention with Single Dose Rifampicin in Contacts of New Leprosy Patients
Willemijn J. Idema, I. Majer, D. Pahan, L. Oskam +2 more
2010PLoS Neglected Tropical Diseases43 citations Open access
Semantic Scholar
Forecasting Lifetime and Aggregate Long-term Care Spending: Accounting for Changing Disability Patterns
C. D. de Meijer, I. Majer, M. Koopmanschap, P. V. van Baal
2012Medical Care42 citations
Semantic Scholar
Life Expectancy and Life Expectancy With Disability of Normal Weight, Overweight, and Obese Smokers and Nonsmokers in Europe
I. Majer, W. Nusselder, J. Mackenbach, A. Kunst
2011Obesity40 citations Open access
Semantic Scholar
Modeling and Forecasting Health Expectancy: Theoretical Framework and Application
I. Majer, Ralph Stevens, W. Nusselder, J. Mackenbach +1 more
2013Demography39 citations Open access
Semantic Scholar
Costs of rheumatoid arthritis in Hungary.
M. Péntek, G. Kobelt, L. Czirják, Z. Szekanecz +8 more
2007Journal of Rheumatology37 citations
Semantic Scholar
Drug survival of second biological DMARD therapy in patients with rheumatoid arthritis: a retrospective non-interventional cohort analysis
T. Wilke, S. Mueller, Sze Lee, I. Majer +1 more
2017BMC Musculoskeletal Disorders30 citations Open access
Semantic Scholar
A European chart review study on early rheumatoid arthritis treatment patterns, clinical outcomes, and healthcare utilization
P. Emery, C. Solem, I. Majer, J. Cappelleri +1 more
2015Rheumatology International29 citations
Semantic Scholar
Palivizumab in the prevention of severe respiratory syncytial virus infection in children with congenital heart disease; a novel cost-utility modeling study reflecting evidence-based clinical pathways in Spain
R. Schmidt, I. Majer, Natalia García Román, Alejandra Rivas Basterra +2 more
2017Health Economics Review19 citations Open access
Semantic Scholar
Cost-effectiveness of 3-year vs 1-year adjuvant therapy with imatinib in patients with high risk of gastrointestinal stromal tumour recurrence in the Netherlands; a modelling study alongside the SSGXVIII/AIO trial
I. Majer, H. Gelderblom, W. B. van den Hout, E. Gray +1 more
2013Journal of Medical Economics19 citations Open access
Semantic Scholar
Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United States
A. Jakubowiak, Ivan Houisse, I. Majer, Á. Benedict +3 more
2017Expert Review of Hematology18 citations
Semantic Scholar
Efficacy, tolerability, and safety of aripiprazole once-monthly versus other long-acting injectable antipsychotic therapies in the maintenance treatment of schizophrenia: a mixed treatment comparison of double-blind randomized clinical trials
I. Majer, F. Gaughran, C. Sapin, M. Beillat +1 more
2015Journal of Market Access & Health Policy15 citations Open access
Semantic Scholar
[Impact of disease progression on health status, quality of life and costs in rheumatoid arthritis in Hungary].
M. Péntek, Z. Szekanecz, L. Czirják, G. Poór +8 more
2008Orvosi Hetilap14 citations Open access
Semantic Scholar
Cost-Effectiveness of Blinatumomab in Pediatric Patients with High-Risk First-Relapse B-Cell Precursor Acute Lymphoblastic Leukemia in France
Megane Caillon, B. Brethon, C. V. van Beurden-Tan, Romain Supiot +4 more
2023PharmacoEconomics - Open11 citations Open access
Semantic Scholar
Burden of Treatment-Induced Peripheral Neuropathy in Patients with Multiple Myeloma in Sweden
H. Nahi, Göran Wålinder, V. Patel, Ying Qu +6 more
2021Acta Haematologica7 citations Open access
Semantic Scholar
Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma: an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trials
K. Weisel, I. Majer, L. Decosta, A. Oriol +5 more
2020Leukemia and Lymphoma7 citations Open access
Semantic Scholar
Panobinostat Plus Bortezomib Versus Lenalidomide in Patients with Relapsed and/or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Treatment Comparison of Survival Outcomes using Patient-level Data
I. Majer, G. van de Wetering, Z. Polányi, A. Krishna +2 more
2017Applied Health Economics and Health Policy7 citations Open access
Semantic Scholar
[Mortality of hospitalized stroke patients in Hungary; 2003-2005].
L. Gulácsi, I. Majer, K. Kárpáti, V. Brodszky +3 more
2007Ideggyógyászati Szemle7 citations
Semantic Scholar
Estimating and Extrapolating Survival Using a State-Transition Modeling Approach: A Practical Application in Multiple Myeloma.
I. Majer, S. Kroep, R. Maroun, Claire E. Williams +2 more
2021Value in Health6 citations Open access
Semantic Scholar
The value of survival gains from therapeutic innovations for US patients with relapsed/refractory multiple myeloma
J. MacEwan, I. Majer, Jacquelyn W. Chou, S. Panjabi
2021Therapeutic Advances in Hematology5 citations Open access
Semantic Scholar
Cost-effectiveness of once weekly carfilzomib 70 mg/m2 plus dexamethasone in patients with relapsed and refractory multiple myeloma in the United States
Shaji K. Kumar, I. Majer, S. Panjabi, R. Medhekar +2 more
2020Expert Review of Hematology5 citations
Semantic Scholar
Modeling Covariate-Adjusted Survival for Economic Evaluations in Oncology
I. Majer, J. Castaigne, S. Palmer, L. Decosta +1 more
2017PharmacoEconomics (Auckland)5 citations Open access
Semantic Scholar
PAR17 BURDEN OF ILLNESS, COSTS AND OUTCOMES OF RHEUMATOID ARTHRITIS IN HUNGARY
M. Péntek, G. Kobelt, Z. Szekanecz, G. Poór +9 more
20054 citations Open access
Semantic Scholar
Time Horizons in Cost Analyses.
I. Majer, Shaji K. Kumar, S. Palmer
2019Journal of the American Medical Association (JAMA)3 citations
Semantic Scholar
Cost-Effectiveness Of Palivizumab In Premature Infants And Children With Chronic Lung Disease In Mexico.
I. Majer, CA Pichardo-Piña, JL Sanchez-Casillas, R. Schmidt +1 more
2015Value in Health3 citations Open access
Semantic Scholar
Comparison of Mean Overall Survival (OS) and Radiographic Progression Free Survival (RPFS) Based on Matching Adjusted Indirect Comparison of Abiraterone Acetate and Enzalutamide for the Treatment of Castration-Resistant Prostate Cancer in Chemotherapy Naïve Patients.
L. Dearden, I. Majer, B. Heeg, J. Liwing +2 more
2014Value in Health3 citations Open access
Semantic Scholar
[Social insurance costs of hospital treatment of stroke in Hungary, 2003-2005].
K. Kárpáti, I. Majer, I. Boncz, Attila Nagy +2 more
2007Ideggyógyászati Szemle3 citations
Semantic Scholar
Evolving Unmet Need in Patients Refractory to Lenalidomide: Overview of the Clinical Trials in Relapsed/Refractory Multiple Myeloma
M. Mateos, R. Medhekar, I. Majer, M. Turgut
20202 citations Open access
Semantic Scholar
A Model to Evaluate the Immunogenicity Costs of Tumour Necrosis Factor-Alpha Inhibitors in Patients with Rheumatoid Arthritis
B. Heeg, I. Majer, J. Stephens, M. Tarallo
20132 citations Open access
Semantic Scholar
Extrapolating Survival in a Heterogeneous Patient Population with Metastatic Melanoma; A Case Study of Integrating Statistical and Clinical Consideration
I. Majer, B. Gueron, S. Kotapati, Van Hout
20132 citations Open access
Semantic Scholar
Modelling and Forecasting Health Expectancy
I. Majer
20122 citations
Semantic Scholar
[Health care costs of acute myocardial infarction in Hungary, 2003-2005].
L. Gulácsi, I. Majer, I. Boncz, V. Brodszky +3 more
2007Orvosi Hetilap2 citations
Semantic Scholar
Matching-adjusted indirect treatment comparisons (MAIC) of sotorasib vs trifluridine/tipiracil (T/T) and regorafenib as monotherapy in chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC).
T. Price, S. Kopetz, Y. Kuboki, H. Prenen +4 more
2023Journal of Clinical Oncology1 citations
Semantic Scholar
PCN222 CARFILZOMIB/LENALIDOMIDE/DEXAMETHASONE IN THE SECOND-LINE SETTING FOLLOWED BY DARATUMUMAB/LENALIDOMIDE/DEXAMETHASONE IN THE THIRD-LINE SETTING VERSUS THE OPPOSITE TREATMENT SEQUENCE: A COST COMPARISON STUDY FROM A BRAZILIAN PRIVATE HEALTH CARE PERSPECTIVE
Straus Tanaka, A. Coggia, A. Arancibia, I. Majer +1 more
2019Value in Health1 citations Open access
Semantic Scholar
Reframing the Value of Treatments for Relapsed/Refractory Multiple Myeloma
S. Ailawadhi, S. Panjabi, M. Campioni, I. Majer +1 more
2018Journal of Managed Care & Specialty Pharmacy1 citations Open access
Semantic Scholar
PSY63 - COST BY OUTCOMES ANALYSIS OF NOVEL TRIPLE-COMBINATION THERAPIES FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA IN BRAZIL
S. Tanaka, R. Maroun, I. Majer, M. Lemos +3 more
2018Value in Health1 citations Open access
Semantic Scholar
Economic Evaluation of Carfilzomib+Dexamethasone (Kd) Vs Bortezomib+Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma (R/RMM)
A. Jakubowiak, I. Majer, Ivan Houisse, Á. Benedict +3 more
20161 citations
Semantic Scholar
Patient reported outcomes (PROs) of multiple myeloma (MM) patients treated with panobinostat (PAN) after ≥2 lines of therapy based on the international phase 3, randomized, double-blind, placebo-controlled, PANORAMA-1 trial.
P. Richardson, S. Lonial, R. Schlossman, A. Roy +4 more
20161 citations
Semantic Scholar
Estimating Utilities for Panobinostat in Combination with Bortezomib and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma; Evidence from the Panorama-1 Trial
I. Majer, A. Krishna, G. van de Wetering, J. San-Miguel +1 more
20151 citations
Semantic Scholar
No Excess Risk of Mortality in Long-Term Survivors of Advanced Melanoma
M. Heisen, M. Tempest, I. Majer
20141 citations Open access
Semantic Scholar
RE1 Factors Influencing Drug Reimbursement Decision in Scotland
M. Charokopou, B. Heeg, I. Majer
20121 citations Open access
Semantic Scholar
[Priorisation in health-care; drug-reimbursement priorities in Hungary in 2004].
K. Kárpáti, A. Brandtmüller, I. Majer, L. Gulácsi
2006Acta pharmaceutica Hungarica1 citations
Semantic Scholar
EE155 Burden of Illness of Adult Patients with Metastatic Colorectal Cancer Bearing the KRAS P.G12C Mutation - A Systematic Literature Review
Z. Chen, M. Rehn, C. Eichinger, I. Majer
2023Value in Health0 citations
Semantic Scholar
PCR117 Meaningful Change Thresholds in Patient-Reported Outcome Scores for Patients with Colorectal Cancer – A Systematic Literature Review
Z. Chen, J. Taieb, M. Rehn, C. Eichinger +1 more
2023Value in Health0 citations
Semantic Scholar
P-249: Real world evidence and outcomes of patients who are exposed or refractory to lenalidomide at the time of first relapse: a Greek registry analysis
E. Kastritis, I. Ntanasis-Stathopoulos, F. Theodorakakou, M. Migkou +13 more
2022Clinical Lymphoma, Myeloma & Leukemia0 citations
Semantic Scholar
PCN4 Carfilzomib in Combination with Dexamethasone (Kd) Versus Pomalidomide in Combination with Bortezomib and Dexamethasone (PVd): A Matching Adjusted Indirect Treatment Comparison (MAIC)
C. Venner, I. Majer, R. Rogoza, A. Yusuf
20210 citations Open access
Semantic Scholar
Cost-effectiveness of once weekly carfilzomib 70 mg/m2 plus dexamethasone in patients with relapsed and refractory multiple myeloma in the United States.
Shaji K. Kumar, I. Majer, S. Panjabi, J. Malacan +3 more
2019Journal of Clinical Oncology0 citations
Semantic Scholar
Letter--Value-Driven Treatment Decisions: Need of the Hour for Relapsed/Refractory Multiple Myeloma.
R. Medhekar, S. Sapra, I. Majer, D. Harrison +1 more
2019Journal of Managed Care & Specialty Pharmacy0 citations Open access
Semantic Scholar
104 Drug Survival of Second Biologic Dmard Therapy in Patients with Rheumatoid Arthritis: Comparison of a Second Anti-Tumour Necrosis Factor with a Second Non-Anti-Tumour Necrosis Factor after Discontinuation of a First Anti-Tumour Necrosis Factor
T. Wilke, S. Mueller, I. Majer, M. Marieke Heisen +2 more
20160 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

L. Gulácsi×8
Invite
L. Gulácsi — researcher profile on SciRah
M. Campioni×7
Invite
M. Campioni — researcher profile on SciRah
V. Brodszky×6
Invite
V. Brodszky — researcher profile on SciRah
S. Panjabi×6
Invite
S. Panjabi — researcher profile on SciRah

×4

Invite

M. Péntek — researcher profile on SciRah

Invite

I. Boncz — researcher profile on SciRah

M. Dimopoulos×4

Invite

M. Dimopoulos — researcher profile on SciRah

K. Kárpáti×4

Invite

K. Kárpáti — researcher profile on SciRah

Invite

R. Medhekar — researcher profile on SciRah

W. Nusselder×3

Invite

W. Nusselder — researcher profile on SciRah

J. Mackenbach×3

Invite

J. Mackenbach — researcher profile on SciRah

P. V. van Baal×3

Invite

P. V. van Baal — researcher profile on SciRah